Prothena | PRTA - Operating Expenses

Stock Price
8.73
Daily Change
-0.18 -2.02%
Monthly
-4.07%
Yearly
-39.75%
Q1 Forecast
8.55

Prothena reported $42.18M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Exelixis USD 341.4M 13.29M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Prothena USD 42.18M 14.25M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025